A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

Active:	No
Cancer Type:	Head and Neck Cancer Hematopoietic Malignancies	NCT ID:	NCT03440437
Trial Phases:	Phase I Phase II	Protocol IDs:	FS118-17101 (primary) NCI-2018-01062
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	invoX Pharma Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT03440437

Summary

This study will be conducted in adult participants diagnosed with advanced tumors to
characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This
is a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed
to systematically assess safety and tolerability, to identify the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced
tumors and to determine the efficacy of FS118 in participants with squamous cell
carcinoma of the head and neck (SCCHN) as monotherapy and in combination with paclitaxel.
In addition to safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy
will also be assessed.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.